Takeda's Dr Andrew Plump recognized with Distinguished Service Award

This marks the fourth time in 18 years that USA India Chamber of Commerce has bestowed this prestigious award at its annual India-US Healthcare and Pharma Summit.

Dr. Andrew Plump /

Dr. Andrew Plump, president of R&D at Takeda, will be recognized with the prestigious "Distinguished Service Award" at the upcoming USAIC's 18th Annual Biopharma & Healthcare Summit in Boston on April 25, a media release announced April 21, 2024.

This award celebrates Dr. Plump's remarkable vision and unwavering commitment to catalyzing industry-academic partnerships, fostering interdisciplinary translational biomedical research and development, and pioneering innovative solutions for a healthier world, said USA India Chamber of Commerce (USAIC).

“As a distinguished physician-scientist, Dr. Andrew Plump's exceptional contributions have indeed propelled significant advancements in the field of biopharma and healthcare. Beyond his scientific achievements, Dr. Plump's leadership and dedication have inspired collaborative efforts aimed at addressing some of the most pressing global health challenges,” said USAIC president Karun Rishi.

His tireless commitment to innovation and collaboration exemplifies the spirit necessary for driving meaningful progress in the life sciences industry, he added.

“Dr. Plump's visionary approach has not only led to scientific breakthroughs but has also fostered partnerships that transcend traditional boundaries, paving the way for interdisciplinary collaboration and collective action. By uniting stakeholders from academia, industry, and government, he has catalyzed efforts to tackle complex healthcare challenges and drive innovation-driven solutions,” USAIC said.

“His leadership exemplifies the collaborative spirit essential for addressing the multifaceted nature of healthcare challenges and driving meaningful progress in medical innovation. Dr. Plump's unwavering dedication to advancing healthcare for all serves as a beacon of inspiration for the entire biomedical community,” it said.

This marks the fourth time in 18 years that USAIC has bestowed this prestigious award, underscoring Dr. Plump's enduring impact and legacy in the field. “We extend our heartfelt congratulations to Dr. Andrew Plump and express our deepest gratitude for his invaluable contributions to the advancement of BioPharma and healthcare innovation,” Rishi said.

Dr. Plump joined Takeda in 2015 to oversee the company’s global R&D organization.

Prior to Takeda, Dr. Plump served as senior vice president, Research & Translational Medicine, deputy to the president of R&D at Sanofi, based in Paris, France. Before Sanofi, he served as vice president, Worldwide Cardiovascular Research head at Merck, where he had direct responsibility for cardiovascular research, preclinical development and translational sciences.

Dr. Plump received his M.D. from the University of California, San Francisco (UCSF), his Ph.D. in cardiovascular genetics with Dr. Jan Breslow at Rockefeller University and his B.S. from the Massachusetts Institute of Technology (MIT).

He completed a residency in Internal Medicine and a fellowship in Medical Genetics at UCSF. Following his clinical training, Dr. Plump trained as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow with Dr. Marc Tessier-Lavigne at UCSF, concurrently assuming faculty responsibilities as an adjunct clinical instructor in the Department of Medical Genetics.            








E Paper